Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Will Omicron finally overpower China’s COVID defences?

The country needs to control the virus until it has boosted vaccination rates in elderly people and reinforced the health-care system.
  1. Dyani Lewis
    View author publications

    You can also search for this author in PubMed  Google Scholar

All eyes are on China as it attempts to quash its largest COVID-19 outbreaks since the early days of the pandemic. More than 62,000 people across all 31 of its provinces are infected, most of them with the fast-spreading BA.2 Omicron variant.

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 604, 17-18 (2022)

doi: https://doi.org/10.1038/d41586-022-00884-z

Updates & Corrections

  • Correction 30 March 2022: An earlier version of this story incorrectly attributed the rates of vaccination in people over 80 on the Chinese mainland to an Airfinity report rather than the Chinese government. This has been corrected.

References

  1. McMenamin, E. et al. Preprint at medRxiv https://doi.org/10.1101/2022.03.22.22272769 (2022).

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links